News & Opinions
Fleishman-Hillard combines strategic counsel with constant innovation.
Sorted by Topic: Healthcare
FDA Schedules Long Overdue Public Hearing on Social Media Use
In November, the FDA will hold a two-day public hearing on big pharma’s social media use, a significant first step in creating long overdue guidelines for the industry. In a recent Advertising Age article, pharma specialisttalks about the importance of social media regulation and the advantage other industries currently have over pharmaceuticals when it comes [...] Read Post
FDA Investigation Surprises Global Pharma Giant
News of the FDA’s investigation into the weight loss drug Alli caught parent company GlaxoSmithKline off guard. But in a recent article by Matthew Perrone in The Associated Press, pharma specialistsays it’s the type of action regulated companies should start to expect as the agency moves toward “a more pro-active public health stance.”
Read: Glaxo Defends [...] Read Post
Canadian Association of Optometrists
Challenge Fleishman-Hillard works with the Canadian Association of Optometrists (CAO) annually to promote preventative eye exams to Canadians during Eye Health Month in October. Disease awareness media coverage requires a creative approach. By using a series of creative communication tools, …Read Post
World COPD Day
Challenge Chronic Obstructive Pulmonary Disease (COPD) is Canada’s fourth leading cause of death and an area of priority for the Canadian Lung Association (CLA) and its respiratory partners across the country. Despite its deadly impact, COPD remains low on the …Read Post
Mental Illness Awareness Week
Challenge In 2002, mental health was a peripheral concern for the federal government. This was despite clear evidence about the cost of mental illnesses: in terms of human suffering and a loss of productivity estimated at $50 billion annually. In …Read Post
The Role of Research and Healthcare
What role will pharmaceutical research and development have in the quickly emerging value-driven healthcare system? In the recent supplement issue of American Health & Drug Benefits, healthcare specialist Kip Piper talks about the “sea of change occurring in Washington” and the effect it will have on future policymaking.
Read: New Government Policies: Opportunities for Supporting Research [...] Read Post
Advancement of Digital Media in the Pharma Sector
Senior members of Fleishman-Hillard’s global healthcare and digital teams join forces for an enlightening look at the “evolution of thought” surrounding Web 2.0 and the healthcare industry. Topics discussed include the increased role social media is playing in patient decisions, lack of clear direction from the FDA despite new leadership, and the agency’s current “vacuum [...] Read Post
Government Overpayments Plague Healthcare Industry
With the struggling U.S. economy as a backdrop, dramatic overpayments on the part of the federal Medicare program strike a particularly sour note. In a recent interview on NPR’s “All Things Considered,” Fleishman-Hillard healthcare specialist Kip Piper discusses the variations in medical product pricing and explains why it’s difficult for the Medicare program and its [...] Read Post
Jane Shapiro speaks on Pandemic Planning to the Canadian Association of University Business Officers
Download MP3 39.5Mb Planning for a possible pandemic should be an extension of the crisis communication planning institutions or corporations are already doing. Pandemic differs from crises often encountered in that it affects the entire community and must be dealt …Read Post
